GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2014-05-07 19:14 |
2014-05-07 CP GENFIT Résultats T1 2014
|
French | 278.4 KB | ||
| 2014-05-05 18:45 |
2014.05.05 PR GENFIT NASH patents
|
English | 262.8 KB | ||
| 2014-05-05 18:45 |
2014.05.05 CP GENFIT Brevets NASH
|
French | 292.4 KB | ||
| 2014-04-15 09:30 |
Transfert sur le marché réglementé d’Euronext à Paris – Compartiment B – Le 17 …
|
French | 747.3 KB | ||
| 2014-04-15 09:30 |
Transfer to the Euronext Paris regulated market – Compartment B – On April 17, …
|
English | 767.1 KB | ||
| 2014-04-14 09:30 |
Potentiel thérapeutique du GFT505 élargi à des pathologies fibrotiques non hépa…
|
French | 766.6 KB | ||
| 2014-04-14 09:30 |
Therapeutic potential of GFT505 widened to non-hepatic fibrotic diseases; New I…
|
English | 136.2 KB | ||
| 2014-04-08 18:45 |
Organisation d’un Workshop au Congrès Annuel de l’EASL autour du GFT505
|
French | 533.1 KB | ||
| 2014-04-08 18:45 |
Organization of a Workshop on GFT505 during the Annual EASL Congress
|
English | 521.2 KB | ||
| 2014-04-03 09:30 |
Compte-rendu de l’AGM du 2 avril 2014
|
French | 747.3 KB | ||
| 2014-04-03 09:30 |
Minutes of the Combined Shareholders’ Meeting of April 2, 2014
|
English | 629.2 KB | ||
| 2014-03-19 17:45 |
GFT505 élimine la NASH et la fibrose dans un modèle reproduisant la situation c…
|
French | 738.0 KB | ||
| 2014-03-19 17:45 |
GFT505 eliminates Nash and Fibrosis in a clinically relevant Disease Model
|
English | 507.7 KB | ||
| 2014-03-12 17:45 |
GENFIT : Résultats Annuels 2013
|
French | 842.3 KB | ||
| 2014-03-12 17:45 |
GENFIT: Annual Results for 2013
|
English | 822.0 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
